Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many solid tumors,
with limited progress made in the area of myeloid malignancies. The low mutational burden …

PURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy
for relapsed/refractory FLT3-mutated (FLT3 mut) acute myeloid leukemia (AML) but seldom …

Preclinical models have shown that blocking PD-1/PD-L1 pathways enhances antileukemic
responses. Azacitidine upregulates PD-1 and IFNγ signaling. We therefore conducted this …

Acute myeloid leukaemia (AML) incidence is age dependent, rising markedly in patients
aged! 60 years. Ageing of the European population may therefore contribute to the reported …

Abstract Azacitidine+ venetoclax, decitabine+ venetoclax, and low-dose cytarabine+
venetoclax are now standard treatments for newly diagnosed older or unfit patients with …

This phase 1b trial (NCT02670044) evaluated venetoclax-idasanutlin in patients with
relapsed/refractory (R/R) acute myeloid leukemia (AML) ineligible for cytotoxic …

Background The powerful 'graft versus leukemia'effect thought partly responsible for the
therapeutic effect of allogeneic hematopoietic cell transplantation in acute myeloid leukemia …

Recent clinical data have shown a synergistic effect of venetoclax in combination with the
hypomethylating agents (HMA) azacitidine and decitabine (complete remission [CR]/CR with …

Background Patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) have
limited treatment options. In preclinical models of AML, inhibition of the PD‐1/PD‐L1 axis …